Weight Loss Drugs and the Future of Weight Management and Wellbeing

Delivery

This report comes in PPT.

Key findings

Euromonitor International’s Weight Loss Drugs Impact Model predicts declines in US weight management sales owing to GLP-1s

Euromonitor International’s Weight Loss Drugs Impact Model evaluates future scenarios of GLP-1 medications’ impact on consumption of weight management products. Its baseline expectation is that a significant shift of weight management users GLP-1s will result in a decline in weight management sales.

Scenario testing results in a range of forecast outcomes, many of which harm weight management prospects

Given the uncertainty implicit in the near-term development of the GLP-1 market, Euromonitor International’s modelling examines several scenarios, and assigns future likelihoods. Many of these scenarios envisage declines in weight management from GLP-1s, though there are some pathways to industry resilience.

Profiling of expected consumers of GLP-1s suggests overlap with weight management categories like meal replacement

Anchoring this modelling is an examination of the consumer groups that are likeliest to adopt GLP-1s for weight loss purposes, and the overlap with current consumers of weight management products. The overlap is starkest in the categories with the most direct weight loss positionings.

Globally, where GLP-1s will spread quickest is dependent on cultural, regulatory and public health factors

Outside the US, Euromonitor International has identified the “next markets” for GLP-1 expansion, based on an evaluation of expected obese populations, surveys examining the universe of consumers looking to lose weight, cultural perspectives on beauty, and the expected cost of, and access to these drugs locally.

Given the challenge presented by GLP-1s, weight management companies are devising strategies to adapt and attract users of these drugs

Weight management companies are examining approaches to engage with users of GLP-1s both during and after their treatment by emphasising messages that will resonate with these consumers (eg addressing the side effects of these drugs, highlighting how these products fit easily within a GLP-1 lifestyle, etc).